Triumph Capital Management’s NovoCure NVCR Stock Holding History

Triumph Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$1.29K	–	1879
2025 Q4	$1.29K	Buy	+100	New	+$1.28K	﹤0.01%	1537

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Triumph Capital Management's NVCR Position: Q1 2026 in Review

Triumph Capital Management sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 100 shares — an estimated $1.29K sold.

Triumph Capital Management first reported a position in NVCR in Q4 2025 and held it in 1 quarter. The position peaked at $1.29K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Triumph Capital Management reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Triumph Capital Management sold 100 NovoCure shares in Q1 2026, an estimated $1.29K.
Triumph Capital Management first reported a position in NovoCure in Q4 2025 and held it in 1 quarter.
Triumph Capital Management's NovoCure position peaked at $1.29K in Q4 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.